Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.5M

Overview

Xiros is a long-established, private medical device company specializing in sterile, implantable orthopedic solutions for soft tissue reconstruction. The company leverages a heritage brand (Neoligaments) and a core technology platform centered on high-strength polyester tapes and innovative fixation devices to address a range of sports medicine procedures. With a fully commercialized product portfolio and a direct-to-surgeon commercial strategy, Xiros operates in the revenue-generating stage, targeting improved patient outcomes through durable, evidence-based surgical devices.

OrthopedicsSports Medicine

Technology Platform

Platform based on high-strength sterile polyester tapes (Poly-Tapes) and mechanical fixation systems (Infinity-Lock Button) for ligament, tendon, and soft tissue reconstruction and repair.

Funding History

2
Total raised:$10.5M
Series A$10M
Grant$500K

Opportunities

The growing global sports medicine market, driven by active aging populations and rising injury rates, presents a significant expansion opportunity.
Consolidation under the Xiros brand and a focus on clinical evidence can strengthen market positioning and surgeon adoption in key regions like the USA.

Risk Factors

Faces intense competition from larger, global orthopedic device companies with greater sales and marketing resources.
Regulatory changes (e.g., EU MDR) could increase compliance costs.
Technological shift towards biologic and resorbable implants may challenge the value proposition of permanent synthetic tapes.

Competitive Landscape

Xiros competes in the crowded sports medicine segment against dominant players like Arthrex, Smith & Nephew, Stryker, and ConMed. Its differentiation lies in its specialized focus on synthetic polyester tape-based solutions and a long heritage in the UK market, positioning it as a niche specialist rather than a full-portfolio provider.